#taltz

[jesusology]

getting my first taltz injection later lads let’s gooooo

i’m probably shouting into the wind here but if anyone has anything to tell me about it (side effects you experienced, if it worked and how quickly it worked yada yada) i would be most appreciative forever 💋

[theboardwalkbody]

Tonight was my 5th injection of Enbrel and idk what was different this time but it hurt like a mfer. The first one I didn't feel at all. The second and third I felt a tiny pinch, which I expected even though the first one I didn't, the fourth I felt nothing again. But this one... It felt like I took a hole puncher to the thigh. It hurts so bad. I didn't do anything different from the others. I've been alternating sites (but sticking to things because it is where I can reach). The injections are twice a week so it's stressing me out. Because I know I need to do it but now I'm going to be anxious over it wondering if it's going to hurt this bad again.

[domripley]

.

[naamahdarling]

What's upsetting to me about the insulin price cap isn't that it happened (I think insulin should be free for everyone), but the fear that Elli Lily will reduce the amount of assistance offered via copay assistance for the drugs that are thousands of dollars for a single dose. Like Taltz ($6586.40) or Verzenio ($14,533.68)

We've already seen this with other biologic or specialty drugs that recently had biosimilars or generics released onto the market, and I'm terrified for how the company will try to 'recoup the losses'

Ooooooooooh good point!

There's no excuse for drugs to be that expensive. Any drug. Don't care what it does.

[mcatmemoranda]

I had a derm pt who has psoriasis and was on Humira. Then got a liver infection and stopped Humira and then changed to Otezla. He stopped Otezla as it was causing vomiting. Now wants to be on another biologic. So the derm PA prescribed Taltz.

These drugs focus on bunting certain parts of the immune system.

[sickzombi]

life update i guess:

-shitty NP didnt listen to me in nov when i told her i was breaking out in psoriasis patches and having more pain than usual

-finger started swelling in dec and ive been in excruciating pain

-said fuck it and found a better doctor in the same network

-saw the new doctor yesterday

-she listened to me and is switching my from humira (Adalimumab) to taltz (Ixekizumab)

-she was so nice! 10/10 love her she actually listened to me and explained everything well!!!

-its getting pre authorization (stupid insurance) but hopefully soon i am able to start it and also hopefully it gets rid of the inflammation ;-;

[an-sceal]

Regarding Taltz injections: ow.

[shubhampawrainfinium]

Psoriasis Treatment Unveiled: The Latest in Therapeutic Advances

According to the report, the global psoriasis therapeutics market is projected to grow at a compound annual growth rate (CAGR) of 9% over the forecast period from 2022 to 2028. The market generated revenue of approximately USD 24 billion in 2022 and is expected to reach nearly USD 44 billion by 2028.

Understanding Psoriasis Therapeutics

Psoriasis is a chronic autoimmune disease that results in the rapid buildup of skin cells, causing scaling and inflammation. Psoriasis therapeutics include a range of treatments such as topical therapies, phototherapy, and systemic treatments, including biologics and small-molecule drugs, aimed at reducing symptoms and managing flare-ups.

Get Sample pages of Report: https://www.infiniumglobalresearch.com/reports/sample-request/825

Market Dynamics and Growth Drivers

The significant growth of the global psoriasis therapeutics market is driven by several factors:

Rising Prevalence of Psoriasis: The global incidence of psoriasis is increasing, leading to a growing patient pool that requires long-term therapeutic solutions. With millions affected worldwide, demand for effective treatments is on the rise.

Advancements in Biologics: Innovations in biologic drugs have transformed the treatment landscape for psoriasis. Biologics, which target specific components of the immune system, have proven highly effective in treating moderate to severe cases, contributing to the market's growth.

Increased Awareness and Diagnosis: Greater awareness of psoriasis and advancements in diagnostic tools are leading to earlier and more accurate diagnoses, ensuring patients receive timely treatment, thereby boosting demand for therapeutics.

Improved Treatment Accessibility: Growing accessibility to advanced treatments, particularly in emerging markets, is also propelling market growth. Governments and healthcare providers are making strides to ensure affordable treatments for patients suffering from psoriasis.

Regional Analysis

North America: North America, particularly the U.S., holds the largest share of the global psoriasis therapeutics market. The region's robust healthcare infrastructure, high psoriasis incidence, and access to advanced biologic treatments drive its market dominance.

Europe: Europe is also a major market for psoriasis therapeutics, with countries like Germany, France, and the U.K. leading the region. Increased healthcare spending and a rising number of biologic approvals are key contributors to the market's growth.

Asia-Pacific: The Asia-Pacific region is expected to witness the fastest growth during the forecast period. Growing awareness, improved healthcare infrastructure, and increasing government initiatives to manage chronic diseases are fueling the demand for psoriasis therapies.

Latin America and Middle East & Africa: These regions are slowly adopting psoriasis treatments due to improving healthcare systems and increased awareness. However, the market here is still in the early stages of development.

Competitive Landscape

The psoriasis therapeutics market is highly competitive, with key players focusing on research and development to introduce more effective and targeted therapies:

AbbVie Inc.: Known for its blockbuster drug Humira, AbbVie is a major player in the psoriasis biologics segment. The company's strong R&D pipeline positions it for continued growth in this market.

Novartis AG: Novartis has made significant strides with its biologic Cosentyx, which has been highly effective in treating moderate to severe psoriasis cases.

Eli Lilly and Company: Eli Lilly's Taltz, another biologic therapy, is making waves in the market with its efficacy and fast-acting results for psoriasis patients.

Johnson & Johnson (Janssen): The company offers the biologic treatment Stelara, which has become a popular option for patients with moderate to severe psoriasis.

Amgen Inc.: Amgen's focus on biologics, particularly Enbrel, has made it a major contender in the psoriasis therapeutics market.

Report Overview : https://www.infiniumglobalresearch.com/reports/global-psoriasis-therapeutics-market

Challenges and Opportunities

While the market is experiencing significant growth, it also faces several challenges:

High Treatment Costs: Biologic therapies, while highly effective, are expensive, limiting access for patients in low- and middle-income regions. Developing cost-effective treatments will be key to expanding the market's reach.

Side Effects and Patient Adherence: Some psoriasis treatments come with side effects, leading to patient adherence issues. Improving the safety profile of these therapies is essential for long-term growth.

Regulatory Approvals: Gaining regulatory approval for new treatments, particularly in regions with strict regulations, can be a hurdle for companies looking to launch innovative therapies.

Despite these challenges, the market presents significant opportunities. The growing trend toward personalized medicine, which tailors treatments to individual patient profiles, is expected to create new avenues for growth. Additionally, ongoing research into novel biologics and small molecules promises to further enhance treatment options for psoriasis patients.

Conclusion

The global psoriasis therapeutics market is poised for robust growth, with projected revenue of nearly USD 44 billion by 2028. With rising disease prevalence, advancements in biologic therapies, and expanding treatment access, the market presents vast opportunities for innovation and investment. As the focus on improving patient outcomes and developing cost-effective solutions increases, the psoriasis therapeutics market is set to witness significant advancements over the forecast period.

[near-seth-experience]

Over the past 6 years with psoriatic arthritis, I wouldn't be surprised if I've forgotten some on this list, but I've tried:

Methotrexate (stopped due to high liver function)

Otezla (didn't work)

Enbrel (didn't work)

Humira (worked for a little while)

Rinvoq (made me nauseous immediately, only lasted a week)

Taltz (didn't work)

Xeljanz (didn't work)

Skyrizi (Only got my loading doses before life got in the way and American Healthcare™ made it impossible for me to continue treatment. It was too soon to tell if it actually helped.)

Today the Rheumatologist decided that after all the stress I got from just trying to get back on Skyrizi, we're not bothering with it anymore. Next up is Remicade. Apparently it's an IV infusion? I've only been hooked up to an IV once berfore that I can remember, so I'm a little nervous about it tbh. He said it might be easier for my (shitty) insurance to authorize, and since I have to go in to the clinic in order have it done, it seems like I don't need to worry about going through specialty pharmacies or copay assistance programs.

If there's fewer hoops for me to jump through to in order to actually receive treatment, I'm all for it.

[softshirringsound]

I saw my rheumatologist yesterday and talked to him about the flares that totally prevented my back from bending from days, made it impossible to do the buttons on my kids’ clothes, and he saw all my swollen and tender joints. And then we added back 15 mg of methotrexate to go with my Taltz and talked about how NSAIDs bother my stomach so much. Then I asked for Tramadol considering all of this shit, and he said it was just a pain killer and doesn’t actually fix anything lmao. I was like I’m on two serious immunosuppressants to fix me!! I need something to mask my pain so I can get my kids dressed!! Goddamn!!!

[miraridoctor]

Psoriasis is an inflammatory autoimmune condition causing rapid buildup of skin cells, often creating raised, scaly, reddened plaques. For those with moderate-severe disease unresponsive to topicals, biologics like Taltz bring profound improvements b... #Mirari #MirariDoctor #MirariColdPlasma #ColdPlasma

[theboardwalkbody]

Mini Life Update because I've been pretty MIA lately.

1. The Unit 3 exam I was last here freaking out about; I got a 78 (with extra credit included) which means it was technically a Below Average grade and I needed to do Remediation Assignments. I originally misread the assignment information and thought I had an entire week to do One Remediation Sheet (they take approximately 30 to 60 minutes each) and study for the cumulative final. So I did the assignment and then Life Happened and I ended up not studying until the Saturday night before the final. Sunday morning I check over the assignment before submitting it (it was due that day) and turns out I needed to do not One remediation sheet but TEN (there were a list and I originally thought I got to pick one to do not that I had to do all of them). So it took me about 5 hours to finish that in a panic because I woke up at noon. Then I tried studying for the final. I had work the morning of the final and never got to go over one of my weak chapters. So guess what the majority of the final was? LOL 🤡

Anyway, I failed the final. I got a 70. It's 28% of my grade but LUCKILY I got a 90 on the first exam and that my average before the final was an 82.53 so the final dropped it down to a 78 and change which means I passed (minimum is 75).

Sounds like good news.

I've been super busy and stressed out however.

Money is really bad and I've been trying to pick up extra work because I won't have work for a week since schools are out for break. So trying to scrape together what I can to not go in the red and to be able to afford food and gas until my next paycheck and to also not go broke from the week off deficit in the subsequent paycheck. Add in to that trying to get together some sort of Christmas stuff and it's just been a lot.

My mental health has been all over the place. Alternating between high anxiety and increased depression. PMS got me having mood swings like crazy. Some days I feel like I'm actually going insane. Tho today, oddly enough, I have been pretty good which usually at this point I'm very much not.

Stressed about my physical health, too, because insurance issues regarding the medication that makes me not in pain (Taltz to control the psoriatic arthritis) and that's a 7k medicine that they're still refusing to cover it so I appear to be SOL starting next year. Can't wait to be bedridden in a few months. Maybe I should drop out of school now since there's no point. LOL

SO ANYWAY. Busy busy busy. Stress. Financially the week off is not the best but mentally it's going to help so much because I definitely feel a bit burned out.

My therapist told me I need to try and pick up some of my old hobbies (at least the one that had brought me the most peace and joy) and/or find new ones and work on self validation and doing things for myself so maybe I'll try working that stuff out.

[mikelogan]

first stelara injection done. by my dad. bc there's no way in hell i can do a prefilled syringe to myself. an autoinjector was fine bc i couldn't see the needle and really didn't have any control other than pressing the button. but it went fine. pinched and then stung, but nothing like taltz was.

[newswireml]

Taltz Safety, Efficacy Stay Robust in Spondyloarthritis at 3 Years#Taltz #Safety #Efficacy #Stay #Robust #Spondyloarthritis #Years

Short-term improvements in axial spondyloarthritis (axSpA) symptoms seen with the interleukin-17A blocker ixekizumab (Taltz) persisted and even increased further among clinical trial participants who continued on the drug for 3 years, without any new safety signals. The proportion of patients achieving “clinically important improvement” in Ankylosing Spondylitis Disease Activity Score (ASDAS)…

[pent1162-blog]

ELlily

礼来(LLY)2022Q4业绩点评(USD) 业绩：2022Q4收入73亿-9%，收入下滑主要因新冠中和抗体业务不可持续，以及美元汇率走高带来约4%的负面影响，去除新冠业务，以固定汇率计算，则收入+10%；non-GAAP净利润18.9亿-4%。Q4收入低于市场预期约9000万，主要因Trulicity销售不及预期。2022FY收入285.4亿+1%，non-GAAP净利润71.86亿+6.7%。 产品销售：Q4包括Verzenio、Mounjaro、Taltz、Trulicity在内的10大核心专利期内品种合计销售额占总收入的70%，增速达到21%。美国以外地区收入下滑6%，主要因汇率波动和药品降价所致，特别是中国区的胰岛素集采以及CDK4/6和PD-1医保降价。Trulicity收入19.4亿+3%，一方面美国以外地区受汇率负面影响约14pp，另一方面不及预期主要因为GLP-1类…

[navalvessels]

Axial Spondyloarthritis market due to see mild growth

Notwithstanding the advancement of medicines with novel components of activity (MOAs), the axial spondyloarthritis (axSpA) market is expected to encounter just gentle development before very long. This is predominantly because of the approaching danger of biosimilars in both the US and EU.

AxSpA is an illness bunch incorporating both ankylosing spondylitis (AS) and non-radiographic Axial Spondyloarthritis Marketed and Pipeline Drugs Market axial spondyloarthritis (nr-axSpA). These circumstances are ongoing autoinflammatory issues of the sacroiliac joints and spine, a region otherwise called the axial skeleton. The sickness is normally analyzed in youthful adulthood to middle age (16-45 years) and has a seven-to nine-year postponement of finding.

A stale market The axSpA market has generally been dependent on enemy of growth rot factor (TNF) treatments that have been accessible for north of 10 years. While the pipeline for drugs in late-stage advancement was deficient with regards to, late improvements have prompted research on original treatment components. This will be crucial in treating the under-analyzed nr-axSpA populace.

While most enemy of TNF treatments have been supported for both AS and nr-axSpA in the 5EU, the US saw its very first nr-axSpA endorsement in Walk 2019. More medication engineers are additionally starting to understand the significance of seeking these sickness impeding therapies to nr-axSpA patients.

Current treatment choices Among right now marketed enemy of interleukin (IL) 17 treatments for AS, Novartis' Cosentyx (secukinumab) and Eli Lilly's recently supported Taltz (ixekizumab) are both being tried in nr-axSpA patients. Concerning drugs in late-stage improvement for axSpA, UCB 's bimekizumab and Kyowa Hakko Kirin's brodalumab are both being tried in AS and nr-axSpA patients all the while. The last option of these items is supposed to just send off in Japan.

Such movement features a more noteworthy consciousness of a generally under-analyzed and under-treated patient segment.

There are a few medicines in late-stage improvement for AS patients just, explicitly Pfizer 's Xeljanz (tofacitinib) and AbbVie 's Rinvoq (upadacitinib). Albeit these Janus kinase inhibitors have been demonstrated to be powerful in treating AS, security concerns with respect to the arrangement of blood clusters from their utilization in rheumatoid joint pain patients has prompted boxed alerts for the two medicines, which might restrict their take-up upon endorsement for AS.

The obstruction of biosimilars Regardless of as of late endorsed medicines and treatments in late-stage improvement with MOAs, the future development of the axSpA market is supposed to be gentle because of the flood of biosimilars in both the US and the EU.

AbbVie's Humira (adalimumab) was the main axSpA drug in 2018. Notwithstanding, it is normal to procure essentially less by 2028 because of endorsement of adalimumab biosimilars in the EU in late 2018, and the normal endorsement of adalimumab biosimilars in the US in 2023. Numerous other originator hostile to TNF drugs are supposed to see biosimilar rivalry over the course of the following ten years, essentially cutting into deals of the originator items. For more MoA insights into the Axial Spondyloarthritis marketed drugs, download a free report sample

Key assessment pioneers (KOLs) talked with by GlobalData by and large concurred that enemy of TNF treatments were probably going to stay the most endorsed medicines for axSpA patients. These KOLs refered to territorial treatment rule proposals that enemies of TNFs be recommended first. Treatment is simply prescribed to continue on toward hostile to IL-17s in case of disappointment (albeit these medicines are contra-shown in patients with fiery entrail sickness, a typical comorbidity of axSpA).

In light of the 2019 update to the US treatment rules, JAK inhibitors are suggested as third-line medicines. These follow enemies of TNFs and against IL-17s. KOLs likewise suggested that biosimilars will introduce a test as they are supposed to be fundamentally less expensive than JAK inhibitors, notwithstanding the last option being little particle treatments.

Generally, the gentle development of the axSpA market in the 7MM throughout the following ten years can be credited to new drugs with novel MOAs arriving at the market, as well as name ventures into the nr-axSpA segment. It will likewise be essentially hampered by the significant expense of new drugs, and rheumatologist experience with promptly accessible enemy of TNF treatments.